Abstract Details

Title Does frequency of COVID-19 differ by disease modifying therapy in MS patients?

Topic Multiple Sclerosis

Presentation(s) MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 014

Objective To determine whether frequency and severity of COVID-19 differ by disease modifying therapy (DMTs) among patients with multiple sclerosis (MS) and other central nervous system immune-mediated disorders.

Background Some authors have reported positive associations with B-cell inhibitors and some with beneficial effects of IFN, but all with numerator data. Here we systematically assessed frequency of COVID-19 on a per-DMT basis in a large New York City-metro area MS clinic population.

Design/Methods We retrospectively reviewed charts for March- September 2020 for all patients on S1P modulators (fingolimod, siponimod), anti-CD20 therapies (rituximab, ocrelizumab), and natalizumab followed at NYU MS Care Center. COVID-19 status was determined by clinical symptoms and laboratory testing where available (SARS-CoV-2 PCR, SARS-CoV-2 IgG).

Results Among 268 patients on natalizumab, 100% of charts were reviewed and 11 patients were determined to have COVID-19 (4% of all natalizumab-treated patients). Among 173 patients on rituximab, 156 charts (90%) were reviewed, and 32 patients were determined to have COVID-19 (21% of all rituximab patients). Among 603 patients on ocrelizumab, 520 (86%) charts were reviewed, and 50 patients were determined to have COVID-19 (10%). Among 270 patients on S1P modulators (253 on fingolimod and 17 on siponimod), 248 (92%) charts were reviewed, and 25 patients were determined to have COVID-19 (10%). Patients with COVID-19 had mean age of 42.1 ± 12.8; 73% were female; 53% white and 26% black American and 93% of patients had diagnosis of MS. Severity status for all COVID-19 cases and multivariable analyses will be presented to ascertain association between DMT and frequency and severity of COVID-19.

Conclusions These data provide important information concerning the frequency and severity of COVID-19 illness for commonly used DMTs, helping MS physicians counsel their patients for treatment decisions during the COVID-19 pandemic.

Authors/Disclosures
Tyler E. Smith, MD PRESENTER	Dr. Smith has received research support from National Multiple Sclerosis Society. Dr. Smith has received personal compensation in the range of $0-$499 for serving as a neurobytes author with ��ɫ��.
Maya Madhavan, MD	Dr. Madhavan has nothing to disclose.
Daniel Gratch, MD	Dr. Gratch has nothing to disclose.
	No disclosure on file
	No disclosure on file
Carrie Sammarco	Carrie Sammarco has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Leigh E. Charvet, PhD (NYU Langone)	Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Johnson & Johnson. Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Springer Healthcare. Dr. Charvet has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for YBrain. Dr. Charvet has stock in Johnson&Johnson.
Gary R. Cutter, PhD (University of Alabama At Birmingham)	Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.
Lauren B. Krupp, MD, FAAN (NYU Langone Medical Center)	Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EBIX. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman LaRoche. Dr. krupp has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for MMMK. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Patrick, Dolan, and Kaufman. Dr. krupp has received intellectual property interests from a discovery or technology relating to health care.
Ilya Kister, MD, FAAN (NYU School of Medicine)	Dr. Kister has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech-Roche. Dr. Kister has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. The institution of Dr. Kister has received research support from Genentech. The institution of Dr. Kister has received research support from Novartis. Dr. Kister has received publishing royalties from a publication relating to health care.
Lana Zhovtis Ryerson, MD, FAAN (Jersey Shore University Medical Center)	Dr. Zhovtis Ryerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Zhovtis Ryerson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi.

��ɫ����

��ɫ����

��ɫ��

��ɫ��